Finally, little is currently known regarding potential roles in CRC progression for novel GEFs, e.g., ARHGEF12 and ARHGEF33, whose overexpression in CRC is associated with poor outcomes (Wu et al., 2023). Here, ARHGEF12 is linked to colorectal carcinoma.